Usheva R
Vutr Boles. 1987;26(1):91-6.
The incidence, severity and prognostic value of thrombocytopenia were studied in 80 patients with myeloma in connection with the clinical stage of the disease and the reaction to the cytostatic treatment. The studies were carried out before the treatment and followed up in the course of the treatment to remission or absence of remission. The results established a progressing thrombocytopenia with the evolution of the disease. Severe thrombocytopenia was established only in stage III, being with an unfavourable prognosis as regards the therapeutic response. The pathogenetic mechanism of its origination are discussed--malignant process in bone marrow, renal insufficiency, advancement of DIC syndrome and toxic effect by the cytostatics administered.
对80例骨髓瘤患者的血小板减少症的发生率、严重程度及预后价值进行了研究，研究内容涉及疾病的临床分期及对细胞毒性治疗的反应。研究在治疗前进行，并在治疗过程中随访至缓解或未缓解。结果显示，随着疾病进展，血小板减少症呈进行性发展。仅在Ⅲ期出现严重血小板减少症，就治疗反应而言，预后不良。文中讨论了其发生的发病机制——骨髓中的恶性过程、肾功能不全、弥散性血管内凝血综合征的进展以及所给予的细胞毒性药物的毒性作用。
